KNSA Stock Overview
A biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kiniksa Pharmaceuticals International, plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.21 |
| 52 Week High | US$28.15 |
| 52 Week Low | US$15.52 |
| Beta | 0.35 |
| 11 Month Change | -18.06% |
| 3 Month Change | -19.08% |
| 1 Year Change | 34.33% |
| 33 Year Change | 74.86% |
| 5 Year Change | 95.84% |
| Change since IPO | 8.94% |
Recent News & Updates
Recent updates
Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story
Oct 07Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 07
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Jul 24Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
Jun 19Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17Shareholder Returns
| KNSA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.2% | -6.5% | -1.0% |
| 1Y | 34.3% | 14.6% | 30.3% |
Return vs Industry: KNSA exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: KNSA exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| KNSA volatility | |
|---|---|
| KNSA Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KNSA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KNSA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 297 | Sanj Patel | www.kiniksa.com |
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024.
Kiniksa Pharmaceuticals International, plc Fundamentals Summary
| KNSA fundamental statistics | |
|---|---|
| Market cap | US$1.50b |
| Earnings (TTM) | -US$9.07m |
| Revenue (TTM) | US$384.10m |
4.0x
P/S Ratio-168.9x
P/E RatioIs KNSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KNSA income statement (TTM) | |
|---|---|
| Revenue | US$384.10m |
| Cost of Revenue | US$149.66m |
| Gross Profit | US$234.44m |
| Other Expenses | US$243.51m |
| Earnings | -US$9.07m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 61.04% |
| Net Profit Margin | -2.36% |
| Debt/Equity Ratio | 0% |
How did KNSA perform over the long term?
See historical performance and comparison